Comparison of safety and outcomes related to remdesivir treatment among dialysis patients hospitalized with COVID-19.

Kirollos E ZakiCheng-Wei HuangHui ZhouJoanie ChungDavid C SelevanMark P RutkowskiJohn J Sim

Published in: Clinical kidney journal (2022)

Among dialysis patients hospitalized with COVID-19, remdesivir was not associated with higher rates of liver injury or ICU admissions, and demonstrated a trend toward lower 30-day mortality.

Keyphrases

end stage renal disease
chronic kidney disease
peritoneal dialysis
liver injury
coronavirus disease
newly diagnosed
sars cov
drug induced
intensive care unit
cardiovascular disease
metabolic syndrome
adipose tissue
risk factors
glycemic control